# LuX-Valve Plus System for Severe or Greater Tricuspid Regurgitation

Study · id `cardio:ct-nct07705594` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07705594](<https://clinicaltrials.gov/study/NCT07705594>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07705594

Browse, organ or system: Heart  
Browse, condition area: Valve and congenital heart disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 126 participants.

## Technical summary

Registry record NCT07705594. Randomized; no masking; primary purpose treatment. Start 2024-10-09 (actual); primary completion 2026-03-06 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 126 participants (enrolled count; ClinicalTrials.gov record NCT07705594, source copy `cardio:ctgov-nct07705594-2026-07-15`, retrieved 2026-10-26)
- Started: 2024-10-09 (actual) (ClinicalTrials.gov record NCT07705594, source copy `cardio:ctgov-nct07705594-2026-07-15`, retrieved 2026-10-26)
- Primary completion: 2026-03-06 (actual) (ClinicalTrials.gov record NCT07705594, source copy `cardio:ctgov-nct07705594-2026-07-15`, retrieved 2026-10-26)
- Completion: 2030-08-06 (anticipated) (ClinicalTrials.gov record NCT07705594, source copy `cardio:ctgov-nct07705594-2026-07-15`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT07705594, source copy `cardio:ctgov-nct07705594-2026-07-15`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07705594-2026-07-15`, retrieved 2026-10-26)

## The registry's words

- Brief title: LuX-Valve Plus System for Severe or Greater Tricuspid Regurgitation
- Condition: Tricuspid Regurgitation (TR)
- Intervention (Device): Transvenous Tricuspid Valve System implantation + OMT
- Intervention (Drug): OMT
- Lead sponsor: Jenscare Scientific
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart valve disease (`cardio:heart-valve-disease`)
- Registry condition terms include this condition: Tricuspid regurgitation (`cardio:tricuspid-regurgitation`)
- Registry lists this organization as the lead sponsor: Jenscare Scientific (`cardio:org-jenscare-scientific`)

## Provenance

Content hash: 915fb7f83e12967e1804512f57e54c52ac8954a9f0e40d4286f70c26be87584a
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
